Dermata Therapeutics(DRMA) - 2024 Q4 - Annual Results

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Anticipated Upcoming Milestones - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 – - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement ...